Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12500157 | 0.86 | SLC6A2 (0.52) | ARALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL498377 | 0.84 | ALDH1A1 (0.56) | MAOBALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL506251 | 0.84 | MAOB (0.46) | MAOBKIF11ARALDH1A1MAPT | |
| SCHEMBL12298013 | 0.82 | MAOB (0.44) | MAOBKIF11ARALDH1A1MAPT | |
| SCHEMBL8422629 | 0.81 | HTT (0.45) | MAOBKIF11ARALDH1A1MAPT | |
| SCHEMBL28301421 | 0.80 | TBXAS1 (0.46) | ALDH1A1MAPTGPR3 | |
| SCHEMBL28263549 | 0.79 | MAOB (0.48) | MAOBKIF11ARALDH1A1MAPT | |
| SCHEMBL7062918 | 0.79 | MAOB (0.48) | MAOBKIF11ARALDH1A1MAPT | |
| SCHEMBL25801726 | 0.79 | MGAT2 (0.51) | MAOBALDH1A1MAPTMMP2HRH3 | |
| SCHEMBL9146549 | 0.78 | MAPT (0.43) | MAOBKIF11ARALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677723-B | 5-HT2A receptor antagonists and their use for treating central nervous system disorders | 瀚远医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| CN-115677723-A | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-113214289-B | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-4058147-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd (JP) | 2022-09-21 | — | — | EP | disclosed |
| CN-114829351-A | Novel antimalarial agents containing heterocyclic compounds | 卫材R&D管理有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-113214289-A | 5-HT2A receptor antagonists and their use for the treatment of central nervous system disorders | 瀚远医药有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2021147818-A1 | 5-HT2A RECEPTOR ANTAGONIST AND APPLICATION THEREOF IN TREATING CENTRAL NERVOUS SYSTEM DISEASES | 瀚远医药有限公司 | 2021-07-29 | — | — | WO | disclosed |
| WO-2021149692-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| EP-0354297-B1 | THIADIAZINES, PROCESS FOR PRODUCTION THEREOF, AND INSECTICIDAL AND ACARICIDAL AGENTS COMPRISING THE THIADIAZINES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-4925863-A | 1,3-DI(1,2,4-TRIAZOL-1-YL)-2-PROPANOL DERIVATIVES SUBSTITUTED WITH A STYRYL GROUP | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| EP-0354297-A1 | Thiadiazines, process for production thereof, and insecticidal and acaricidal agents comprising the thiadiazines | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-02-14 | — | — | EP | disclosed |
| US-4837364-A | REACTION OF HALOBENZENE WITH TRIFLUOROETHANOL | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-06-06 | — | — | US | disclosed |
| EP-0174769-A1 | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-03-19 | — | — | EP | disclosed |
| US-3994907-A | Coumarin derivatives, their preparation and their use as optical brightening agents | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | QDPR, DHODH, THPO | MAOB 1815/4885KIF11 2725/4885AR 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.